Home MAPK Raf inhibitor - PDGFR inhibitor - VEGFR inhibitor - FLT3 inhibitor - c-Kit inhibitor - FGFR inhibitor - Ferroptosis activator - Autophagy activator - Apoptosis related activator Sorafenib (BAY 43-9006) tosylate

Sorafenib (BAY 43-9006) tosylate

Catalog No.S1040

For research use only.

Sorafenib (BAY 43-9006) tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Sorafenib (BAY 43-9006) tosylate Chemical Structure

CAS No. 475207-59-1

Selleck's Sorafenib (BAY 43-9006) tosylate has been cited by 233 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Related Compound Libraries

Other Raf Products

Download Inhibitor Catalog

Download Inhibitor Catalog
Raf Signaling Pathways

Raf Signaling Pathway Map

Biological Activity

Description Sorafenib (BAY 43-9006) tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)		 VEGFR2/Flk1 [1]
(Cell-free assay)		 B-Raf [1]
(Cell-free assay)		 B-Raf (V599E) [1]
(Cell-free assay)		 PDGFRβ [1]
(Cell-free assay)		 Click to View More Targets
6 nM 15 nM 22 nM 38 nM 57 nM
In vitro

Sorafenib tosylate inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib tosylate also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib tosylate weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib tosylate markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib tosylate potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib tosylate inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib tosylate significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib tosylate inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-435 NWLjclNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrWOFghcA>? MYnHTVUxRTJizszN NWX2W4o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA3OjdpPkKyOVYxPjJ5PD;hQi=>
UACC257 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPaeJQ1QCCq NEHBN|NIUTVyPUKg{txO NGTjeZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW2NFYzPyd-MkK1OlA3Ojd:L3G+
MCF7 NYiwfZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fXW|Q5KGh? MWTHTVUxRTJwNTFOwG0> NXraflJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA3OjdpPkKyOVYxPjJ5PD;hQi=>
EKVX NYrrcmFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq5OFghcA>? Mln2S2k2OD1{LkWg{txO NVSwOYRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA3OjdpPkKyOVYxPjJ5PD;hQi=>
HT-29 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu0PEBp NYnUPWtZT0l3ME2yMlUh|ryP MkLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NkC2NlcoRjJ{NU[wOlI4RC:jPh?=
SNB19 NHX6Om5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vT[FQ5KGh? M3TtcWdKPTB;Mz6yJO69VQ>? NVW3TIx7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA3OjdpPkKyOVYxPjJ5PD;hQi=>
OVCAR3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi0PEBp NXy0Om14T0l3ME2zMlIh|ryP Mn\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NkC2NlcoRjJ{NU[wOlI4RC:jPh?=
CAKI-1 NFnIdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP4e4I1QCCq M{TMUmdKPTB;Mz6yJO69VQ>? NYnKdYdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA3OjdpPkKyOVYxPjJ5PD;hQi=>
SW620 NYLIXYRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DoVlQ5KGh? MV3HTVUxRTNwMjFOwG0> NHPkTnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW2NFYzPyd-MkK1OlA3Ojd:L3G+
TK10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKwOFghcA>? NFnj[otIUTVyPUWg{txO MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV4ME[yO{c,OjJ3NkC2Nlc9N2F-
endothelial precursor cells MXXGeY5kfGmxbjDhd5NigQ>? NILTPVhKdmirYnn0bY9vKG:oIHXu[I91cGWuaXHsJINwemRiYYLlZUBnd3KvYYTpc44hcW5iZX7kc5Rp\WyrYXygdJJm[3W{c3;yJINmdGy|IHL5JGNFOzFiY3;y[EBiemWjIHTleIVkfGmxbjDiZZNm\CCyaHXuc5R6eGmlIHTyeYch\Gm|Y3;2[ZJ6KGKjc3XkJIF{e2G7LDDJR|UxKD1iMD6wNFQzOSEQvF2u NX[1OI9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFk3PjZpPkKyOFA6PjZ4PD;hQi=>
Sf9 MVfGeY5kfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRicnXjc41jcW6jboSgbJVu[W5iVlXHSnIzKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkhemGmaX;t[ZRzcWNiYYPzZZktKEmFNUCgQUAxNjBzMkWg{txONg>? NEDodXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2PFIxQSd-MkSzOlgzODl:L3G+
endothelial precursor cells/ADSC cells MlTaWI95cWOrdImgZZN{[Xl? MmD0WI95cWOrdImgbY4h\W6mb4To[Yxq[WxicILlZ5Vze2:{IHPlcIx{KGOxLXP1cJR2emWmIIfpeIghe3S{b33hcEBxemWldYLzc5IhSUSVQzDj[YxteyCkeTD0c5RidCCwdXPs[Ykh[2:3boSg[IV1\WO2aX;uJIJie2WmIIDo[Y5wfHmyaXOg[JJ2\yCmaYPjc5ZmenliYnHz[YQh[XO|YYmsJGVEPTBiPTC1MlQ3KM7:TT6= NXLQPGl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFk3PjZpPkKyOFA6PjZ4PD;hQi=>
endothelial precursor cells MUDGeY5kfGmxbjDhd5NigQ>? NVjRboFtUW6qaXLpeIlwdiCxZjDj[YxtKG2rZ4LheIlwdiCrbjDlcoRwfGinbHnhcEBxemWldYLzc5Ih[2WubIOgZpkhV3KrczDj[YxtKG2rZ4LheIlwdiCtaYSgZoF{\WRicHjlco91gXCrYzDkdpVoKGSrc3PveoVzgSCkYYPl[EBie3OjeTygTWM2OCB;IEG2Mlch|ryPLh?= NVy5U4pPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFk3PjZpPkKyOFA6PjZ4PD;hQi=>
RD NF3ZOlFyUFSVIHHzd4F6 MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M4jJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NYXLPIU1eUiWUzDhd5NigQ>? Ml7xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NXjJRnRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MXrxTHRUKGG|c3H5 MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NU\QbJRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot LC3-I / LC-3II / ATG5 ; p-STAT3 / STAT3/ Mcl-1 ; β-catenin / Survivin / Mcl-1 / PTMA ; pERK / ERK ; p-PKM2(Y105) / PMK2 / Caspase-9 ; RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204) ; Cyclin D1 23392173 26517516 22286758 26959741 22941289 26039995
Immunofluorescence p65 ; cytochrome c 22286758 22278289
Growth inhibition assay Cell viability 26039995
ELISA TGF-beta / CD206 ; Caspase-9 / Caspase-3 26158762 30923462
In vivo Oral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib tosylatetreatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib tosylate treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Biochemical assays:

    Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:[1]
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.
Animal Research:[1]
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% Cremophor EL, 2% N,N-dimethylacetamide
For best results, use promptly after mixing.

 30 mg/mL (suspension)

Chemical Information

Molecular Weight 637.03
Formula

C21H16ClF3N4O3.C7H8O3S
CAS No. 475207-59-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05068752 Recruiting Drug: Vemurafenib|Drug: Sorafenib Pancreas Cancer HonorHealth Research Institute|Bayer|Genentech Inc. October 28 2021 Phase 2
NCT04763408 Recruiting Drug: Lenvatinib|Drug: Sorafenib Carcinoma Hepatocellular Eisai Inc. April 9 2021 --
NCT04000737 Recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. January 10 2020 Phase 2
NCT03958669 Unknown status -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research November 1 2019 --
NCT03764293 Active not recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. June 10 2019 Phase 3
NCT03582618 Active not recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Sorafenib (BAY 43-9006) tosylate | Sorafenib (BAY 43-9006) tosylate supplier | purchase Sorafenib (BAY 43-9006) tosylate | Sorafenib (BAY 43-9006) tosylate cost | Sorafenib (BAY 43-9006) tosylate manufacturer | order Sorafenib (BAY 43-9006) tosylate | Sorafenib (BAY 43-9006) tosylate distributor